Dupuytren's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Dupuytren's disease markets are expected to exhibit a CAGR of 3.76% during 2024-2034.
The Dupuytren's disease market has been comprehensively analyzed in IMARC's new report titled "Dupuytren's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dupuytren's disease, also referred to as Dupuytren's contracture, is a chronic ailment that affects the connective tissue in the palm of the hand. It is characterized by the formation of nodules and thickened cords of tissue beneath the skin of the palm and fingers. As the disease progresses, these cords can contract and cause the fingers to bend towards the palm, resulting in a characteristic hand deformity. The little finger and the ring finger are most commonly affected, although other fingers can also be involved. The severity of symptoms can vary among patients, with some experiencing mild contractures that do not significantly impact hand function, while others may face more pronounced deformities that interfere with daily activities and overall hand mobility. Diagnosing Dupuytren's disease involves a comprehensive evaluation by a qualified healthcare professional, typically a hand surgeon or hand specialist. The diagnosis is mainly based on a physical examination of the hand, where the characteristic nodules, cords, and finger contractures are assessed. The healthcare professional will also inquire about the patient's medical history and any family history of Dupuytren's disease. In some cases, numerous imaging tests, such as ultrasound and MRI, may be used to visualize the affected tissues and determine the extent of the condition.
The rising cases of specific genetic variations that affect the genes involved in collagen production, metabolism, and tissue remodeling are primarily driving the Dupuytren's disease market. In addition to this, the increasing incidences of abnormal collagen deposition and metabolism in the fascia, which result in the development of nodules and cords that lead to finger contractures, are also creating a positive outlook for the market. Moreover, the widespread adoption of corticosteroid injections for decreasing inflammation, alleviating symptoms, and potentially slowing down the formation of collagen is further bolstering the market growth. Apart from this, the inflating application of lipografting, which aims to restore the natural architecture and softness of the hand, thereby providing symptomatic relief and improving hand function, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of several minimally invasive surgical techniques, such as endoscopic fasciotomy and needle aponeurotomy, that aid in achieving effective contracture release while minimizing postoperative complications and scarring is expected to drive the Dupuytren's disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Dupuytren's disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Dupuytren's disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dupuytren's disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Dupuytren's disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Dupuytren's disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Dupuytren's disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Dupuytren's disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Dupuytren's disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Dupuytren's disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Dupuytren's disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Dupuytren's disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Dupuytren's disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Dupuytren's disease across the seven major markets?
What is the size of the Dupuytren's disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Dupuytren's disease?
What will be the growth rate of patients across the seven major markets?
Dupuytren's Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Dupuytren's disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dupuytren's disease market?
What are the key regulatory events related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by status related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by phase related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by route of administration related to the Dupuytren's disease market?
The Dupuytren's disease market has been comprehensively analyzed in IMARC's new report titled "Dupuytren's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dupuytren's disease, also referred to as Dupuytren's contracture, is a chronic ailment that affects the connective tissue in the palm of the hand. It is characterized by the formation of nodules and thickened cords of tissue beneath the skin of the palm and fingers. As the disease progresses, these cords can contract and cause the fingers to bend towards the palm, resulting in a characteristic hand deformity. The little finger and the ring finger are most commonly affected, although other fingers can also be involved. The severity of symptoms can vary among patients, with some experiencing mild contractures that do not significantly impact hand function, while others may face more pronounced deformities that interfere with daily activities and overall hand mobility. Diagnosing Dupuytren's disease involves a comprehensive evaluation by a qualified healthcare professional, typically a hand surgeon or hand specialist. The diagnosis is mainly based on a physical examination of the hand, where the characteristic nodules, cords, and finger contractures are assessed. The healthcare professional will also inquire about the patient's medical history and any family history of Dupuytren's disease. In some cases, numerous imaging tests, such as ultrasound and MRI, may be used to visualize the affected tissues and determine the extent of the condition.
The rising cases of specific genetic variations that affect the genes involved in collagen production, metabolism, and tissue remodeling are primarily driving the Dupuytren's disease market. In addition to this, the increasing incidences of abnormal collagen deposition and metabolism in the fascia, which result in the development of nodules and cords that lead to finger contractures, are also creating a positive outlook for the market. Moreover, the widespread adoption of corticosteroid injections for decreasing inflammation, alleviating symptoms, and potentially slowing down the formation of collagen is further bolstering the market growth. Apart from this, the inflating application of lipografting, which aims to restore the natural architecture and softness of the hand, thereby providing symptomatic relief and improving hand function, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of several minimally invasive surgical techniques, such as endoscopic fasciotomy and needle aponeurotomy, that aid in achieving effective contracture release while minimizing postoperative complications and scarring is expected to drive the Dupuytren's disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Dupuytren's disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Dupuytren's disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dupuytren's disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Dupuytren's disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Dupuytren's disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Dupuytren's disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Dupuytren's disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Dupuytren's disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Dupuytren's disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Dupuytren's disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Dupuytren's disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Dupuytren's disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Dupuytren's disease across the seven major markets?
What is the size of the Dupuytren's disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Dupuytren's disease?
What will be the growth rate of patients across the seven major markets?
Dupuytren's Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Dupuytren's disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dupuytren's disease market?
What are the key regulatory events related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by status related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by phase related to the Dupuytren's disease market?
What is the structure of clinical trial landscape by route of administration related to the Dupuytren's disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DUPUYTREN'S DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DUPUYTREN'S DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DUPUYTREN'S DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DUPUYTREN'S DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DUPUYTREN'S DISEASE - UNMET NEEDS
10 DUPUYTREN'S DISEASE - KEY ENDPOINTS OF TREATMENT
11 DUPUYTREN'S DISEASE - MARKETED PRODUCTS
11.1 List of Dupuytren's Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Xiaflex (Collagenase clostridium histolyticum) - BioSpecifics Technologies Corporation/Endo International
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DUPUYTREN'S DISEASE - PIPELINE DRUGS
12.1 List of Dupuytren's Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. DUPUYTREN'S DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DUPUYTREN'S DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DUPUYTREN'S DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dupuytren's Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Dupuytren's Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dupuytren's Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dupuytren's Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Dupuytren's Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dupuytren's Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dupuytren's Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dupuytren's Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dupuytren's Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dupuytren's Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dupuytren's Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dupuytren's Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dupuytren's Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dupuytren's Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dupuytren's Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dupuytren's Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dupuytren's Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dupuytren's Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dupuytren's Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dupuytren's Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dupuytren's Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dupuytren's Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dupuytren's Disease - Access and Reimbursement Overview
16 DUPUYTREN'S DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DUPUYTREN'S DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DUPUYTREN'S DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DUPUYTREN'S DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DUPUYTREN'S DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DUPUYTREN'S DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DUPUYTREN'S DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DUPUYTREN'S DISEASE - UNMET NEEDS
10 DUPUYTREN'S DISEASE - KEY ENDPOINTS OF TREATMENT
11 DUPUYTREN'S DISEASE - MARKETED PRODUCTS
11.1 List of Dupuytren's Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Xiaflex (Collagenase clostridium histolyticum) - BioSpecifics Technologies Corporation/Endo International
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DUPUYTREN'S DISEASE - PIPELINE DRUGS
12.1 List of Dupuytren's Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. DUPUYTREN'S DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DUPUYTREN'S DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DUPUYTREN'S DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dupuytren's Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Dupuytren's Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dupuytren's Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dupuytren's Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Dupuytren's Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dupuytren's Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dupuytren's Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dupuytren's Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dupuytren's Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dupuytren's Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dupuytren's Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dupuytren's Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dupuytren's Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dupuytren's Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dupuytren's Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dupuytren's Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dupuytren's Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dupuytren's Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dupuytren's Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dupuytren's Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dupuytren's Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dupuytren's Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dupuytren's Disease - Access and Reimbursement Overview
16 DUPUYTREN'S DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DUPUYTREN'S DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DUPUYTREN'S DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
